GlassScriptPhysician profile
Lorelei A Fen
NPI 1649312893
$988.17
in general payments reported to CMS, 2019-2025
27 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2023: $214 · 2024: $200 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $198.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $104.48 | 2023-2025 | Lynparza, Enhertu |
| Astellas Pharma US INC | $59.26 | 2023-2024 | Xtandi |
| Novartis Pharmaceuticals Corporation | $59.08 | 2023-2025 | |
| Pfizer INC. | $55.62 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.59 | 2023 | |
| Merck Sharp & Dohme LLC | $41.92 | 2024-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $41.49 | 2023-2025 | Erleada, Talvey, Darzalex |
| Regeneron Healthcare Solutions, INC. | $37.98 | 2024-2025 | Libtayo |
| Glaxosmithkline, LLC. | $35.10 | 2025 | Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $33.13 | 2023-2025 | Opdivo |
| Genmab U.S., INC. | $20.59 | 2024 | Epkinly |
| Pharmacosmos Therapeutics INC. | $19.92 | 2023 | Monoferric |
| Lilly USA, LLC | $19.45 | 2024 | Verzenio |
| Takeda Pharmaceuticals U.S.A., INC. | $19.38 | 2025 | Iclusig |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $18.66 | 2025 | Carvykti |
| Agios Pharmaceuticals, INC. | $18.36 | 2025 | Pyrukynd |
| Tersera Therapeutics LLC | $18.14 | 2025 | Xermelo |
| Pharmaessentia USA Corporation | $17.60 | 2025 | Besremi |
| Jazz Pharmaceuticals INC. | $16.67 | 2021 | |
| Stemline Therapeutics INC. | $16.58 | 2024 | Orserdu |
| Array Biopharma INC | $16.21 | 2024 | Tukysa, Braftovi, Mektovi |
| Abbvie INC. | $15.90 | 2025 | |
| Celgene Corporation | $15.60 | 2023 | Reblozyl |
| Coherus Oncology, INC. | $14.94 | 2021 | |
| Invivyd INC | $14.87 | 2025 | Pemgarda |
| Seagen INC. | $12.70 | 2023 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorelei Fen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.